

Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

| | |
|-----------------------------|--|
| Title | MicroRNA expression in colorectal cancer. |
| Author(s) | Hogan, Niamh M.; Joyce, Myles R. |
| Publication Date | 2012-12-17 |
| Publication Information | Hogan NM, Joyce MR, Kerin MJ (2012) 'MicroRNA expression in colorectal cancer'. Cancer Biomarkers, 11 (6):239-243. |
| Publisher | IOS Press |
| Link to publisher's version | http://dx.doi.org/10.3233/CBM-2012-00278 |
| Item record | http://hdl.handle.net/10379/3825 |
| DOI | http://dx.doi.org/10.3233/CBM-2012-00278 |

Downloaded 2024-04-24T23:48:09Z

Some rights reserved. For more information, please see the item record link above.



MicroRNA expression in colorectal cancer

Niamh M. Hogan*, Myles R. Joyce and Michael J. Kerin

Discipline of Surgery, School of Medicine, National University of Ireland, Galway, Ireland

1. Introduction

Colorectal cancer is a common disease entity with a multi-factorial aetiology which remains poorly understood. It is estimated that in 2008, colorectal cancer was responsible for 8% of all cancer deaths, making it the fourth most common cause of death from cancer [10]. Prognosis is heavily linked to stage at diagnosis. The major cause of death is development of metastasis in liver, abdominal lymph nodes, and lung, for which there is no cure [21]. According to the most recently defined American Joint Committee on Cancer (AJCC) system for colonic adenocarcinoma, 5-year stage-specific survivals were 93.2% for stage I disease compared with 8.1% for stage IV [34], highlighting a need for novel early detection strategies. Colorectal cancer, at least theoretically, is a disease entity which is amenable to early detection, since it exhibits a stepwise progression of carcinogenesis from benign polyps to adenocarcinoma, over a period of time. The majority of national screening programmes currently centre on the use of colonoscopy or faecal immunohistochemistry/occult blood testing. Colonoscopy is an expensive, invasive procedure which carries a significant risk of intestinal perforation (1:700). Faecal testing is more cost effective and less invasive but sacrifices sensitivity and specificity. Carcinoembryonic antigen, the only blood test currently available, exhibits low sensitivity and specificity. Hence, there is great need for new biomarkers for early detection of CRC.

2. MicroRNA biochemistry and function

First described by Lee et al. in 1993, microRNAs are a class of small (19–25 ribonucleotides) non-coding

RNAs [25]. Upon discovery, each microRNA is assigned a numerical identifier and the number identified in humans to date approaches 1000 [12,30]. In brief, the maturation of microRNAs is thought to be triphasic [3]. Initially, transcription of pri-miRNA (primary transcripts) occurs in the nucleus [3,13]. They are then processed by an RNA specific ribonuclease enzyme complex (DROSHA) and cleaved into shorter 970 nucleotide precursor-microRNAs [41,46]. The final cleavage step occurs after transportation to the cytoplasm by exportin 5 [41].

MicroRNAs are known to regulate gene expression at a post-transcriptional level by acting on messenger RNA (mRNA) targets. Through this mechanism, they may induce degradation of mRNA or translational inhibition. Found in both prokaryotes and eukaryotes, microRNAs are also known to post-transcriptionally regulate a number of key cellular processes including differentiation, proliferation, progression and apoptosis [4]. In fact, it is now widely accepted that microRNAs are involved in almost all cellular processes to some degree. Since these processes represent central mechanisms of tumorigenesis, it is unsurprising that microRNAs became the subject of international interest in cancer detection and therapeutics. The focus of this review will remain on cancer detection and the use of microRNAs as biomarkers.

3. MicroRNAs in cancer

Almost a decade after microRNAs were first described, Calin et al. published the first study linking microRNAs and cancer [5]. The authors identified a translocation-induced deletion at chromosome 13q14.3 in a model of B-cell chronic lymphocytic leukaemia, with associated loss of miR-15a and miR-16-1 [5]. Since microRNAs represent key players in cellular processes crucial to carcinogenesis, over-expression of

*Corresponding author: Dr. Niamh M. Hogan, Postgraduate research fellow, Department of Surgery, University College Hospital Galway, Galway, Ireland. E-mail: niamhogan@gmail.com.

oncogenic microRNAs contributes to tumour development through promotion of migration, invasion and proliferation [30,36]. Conversely, increased expression of tumour suppressor microRNAs may have the opposite effect [30,36]. Aberrant expression of these small molecules has now been reported in many cancers, including colorectal [26]. Most importantly from a biomarker perspective, microRNA expression has recently been shown to be specific to tissue type and cancer type [15,44,46].

4. MicroRNAs in colorectal cancer

Soon after Calin et al. published their work linking microRNAs with cancer, researchers began to publish microRNA deletions associated with other haematological malignancies. Shortly afterwards, Michael et al. identified mir-143 and mir-145 as novel dysregulated microRNAs in colorectal cancer [29]. In the past decade, almost 400 further dysregulated microRNAs have been reported in colorectal cancer. These microRNAs are listed in Table 1. Ma et al. recently conducted a systematic review of candidate microRNA biomarkers in colorectal cancer and compiled a list of six microRNAs most consistently found to be dysregulated in colorectal cancer tissue in the literature. These microRNAs were mir-106a (up regulated), miR-125a, miR-133a, miR-145, miR-30a-3p and miR-139 (all down-regulated) [28]. The mechanism underpinning this dysregulation is not yet understood, however researchers have proposed that DNA hypermethylation may result in down-regulation of specific microRNAs. Histone acetylation and enzymatic mechanisms that influence microRNA processing have also been implicated [35]. Although the full extent of the human microRNA-ome has yet to be elucidated and although the mechanism of dysregulation of microRNAs in colon cancer remains largely unknown, a growing body of evidence supports the theory that specific microRNA expression patterns are associated with colorectal cancer. The potential implications of this association are far-reaching.

MicroRNAs have also been shown to correlate with clinicopathological features in colorectal cancer. MiR-143 and -145 were shown by Michael et al. to be consistently reduced in tissue during the early adenomatous stage of colorectal cancer development [29]. Furthermore, an association between miR-21 expression in tissue, clinicopathological stage and lymph node positivity has also been observed by Slaby et al. [40], with other studies supporting an association between high miR-21 expression and poor survival [38].

Table 1
MicroRNAs up-regulated and down-regulated in colorectal cancer

| Collated list of dysregulated microRNAs in colorectal cancer with proposed target genes [2,6,8,28,33,46,47] | |
|---|---------------------------------|
| let 7a | c-Myc, DLD-1, Ras |
| miR-1 | FSCN1 |
| miR-9 | ACOT7, SLC45A1 |
| miR-17 | E2F1 |
| miR-17-3p | MMP23B, CHD5 |
| miR-17-5p | MMP23B, CHD5 |
| miR-19a | KLHL17 |
| miR-21 | Cdc24A, Pcd4, PTEN, Sprouty2 |
| miR-25 | CAMTA1, KIF1B |
| miR-29a | CCNL2, CAMTA1 |
| miR-29b | CCNL2, CAMTA1 |
| miR-31 | FIH-1, KIF1B, ZUBR1 |
| miR-34a | E2F1, SIRT1 |
| miR-92 | CAMTA1, KIF1B |
| miR-95 | UBE4B |
| miR-100 | TARDBP, FRAP1 |
| miR-101 | COX-2 |
| miR-106a | E2F1 |
| miR-124a | CAMTA1, RERE |
| miR-125a | TP73, E2F3 |
| miR-126 | P85beta, KIF1B, HP1BP3 |
| miR-128a | CPSF3L |
| miR-128b | CPSF3L |
| miR-133b | c-Met |
| miR-135a | APC, GNB1, CAMTA1 |
| miR-135b | APC, GNB1, CAMTA1 |
| miR-137 | Cdc42, LSD-1 |
| miR-142-3p | CAMTA1 |
| miR-143 | Ras, DNMT3A, ENO1, KIF1B, K-Ras |
| miR-145 | IRS1, STAT1, YES, FLI1 |
| miR-146a | SPEN |
| miR-148a | KLHL17, PRKCZ |
| miR-154* | GNB1, LZIC |
| miR-155 | MSH2, MSH6, MLH1 |
| miR-181b | CYLD |
| miR-182 | CCNL2, KIF1B |
| miR-183 | KLHL17, TNFRSF25 |
| miR-192 | CTNNBIP1 |
| miR-195 | Bcl-2 |
| miR-200c | TGFβ2, ZEB1 |
| miR-203 | Sox2, Klf4 |
| miR-328 | ATAD3C |
| miR-335 | CAMTA1, KIF1B |
| miR-338 | WDR8, TNFRSF25 |

5. MicroRNAs and the colorectal tumour microenvironment

Investigation of colorectal carcinogenesis initially focussed solely on epithelial tumour cells but it is now known that epithelial cells exist within a supportive stromal network and that significant stromal dysregulation also occurs [17]. This dynamic crosstalk characterised by a bidirectional relationship between stromal and epithelial cells, impacts heavily on core tumour characteristics including degree of hypoxia, angiogen-

esis and inflammation [17,35]. These characteristics directly impact on prognosis and the level of angiogenesis has been reported as a survival predictor for patients with colorectal cancer [11,20]. Recent studies have implicated microRNAs in regulating hypoxia and interacting with inflammatory factors such as VEGF in the tumour microenvironment [35]. It has been proposed that the regulation of angiogenesis in colorectal tumours involves an interplay between anti-angiogenic microRNAs (miR-20a and mir-221) and pro-angiogenic microRNAs (let-7f and mir-126) [16,22,35].

6. MicroRNAs as biomarkers

An ideal biomarker should be sampled in as non-invasive a manner as possible and should display a good sensitivity and specificity profile [24]. Given that microRNAs are aberrantly expressed in colorectal cancer since colorectal cancer is a disease in great need of a biomarker, these candidates warrant extensive investigation. Furthermore, microRNAs are extremely stable molecules and have been shown to preserve their integrity for up to a decade in formalin-fixed paraffin embedded colorectal cancer tissue samples [33,45].

Cancer-associated RNAs have been described in the circulation of cancer patients for more than a decade and since patients routinely undergo blood test in the diagnostic work-up of even minor illnesses, this route holds potential in the pursuit of a minimally invasive sampling medium [42]. Recently, several groups have reported that circulating microRNAs exist and can be detected in the serum and plasma [31]. Expression profiles of circulating microRNAs have been more extensively investigated in breast and prostate cancer, however recent studies reveal potential promise in colorectal cancer [18]. Ng et al. report elevated miR-17-3p and miR-92 levels in the serum of patients with colorectal cancer with significant reduction in levels after tumour resection [32]. In the same study MiR-92 was also an effective discriminator between colorectal and gastric cancers [32]. Huang et al. examined plasma samples from over 150 colorectal cancer patients and report that plasma miR-29a and miR-92a have strong potential as novel non-invasive biomarkers for early detection of CRC. With combined analysis of both microRNAs they achieved a 83.0% sensitivity and 84.7% specificity in discriminating colorectal cancer from normal controls [18]. When variability of expression is taken into consideration, it appears that a tumour-specific panel of microRNAs, rather than the use of single microRNAs

in isolation, may represent a more pragmatic opportunity for increased sensitivity and specificity in biomarker candidates [43].

In pursuit of a minimally-invasive biomarker, colorectal cancer presents the opportunity to use faeces as a potential source of a biomarker candidate. Recently, Link et al. reported that microRNAs are abundantly present in stool and can be easily and reproducibly detected in stool specimens using standard microRNA extraction techniques [27]. Furthermore, Ahmed et al. proposed that a panel of microRNA isolated from faecal samples may hold greater sensitivity and specificity than currently used screening genomic, methylomic or proteomic methods for colon cancer [1]. Interestingly, a recent study by Kalimutho et al. found miR-34b/c hypermethylation in 75% (21 out of 28) of faecal specimens examined indicating potential as a non-invasive screening tool [19]. Larger patient studies are required to validate and develop these novel strategies.

As our understanding of microRNA expression in colorectal cancer develops, it may be possible not simply to distinguish between cancers and controls, but to delineate degrees of disease activity, core tumour characteristics and predicted response to treatment. It is universally acknowledged that individualisation of therapy represents the future of cancer care. Early detection of tumours, as well as the ability to differentiate between cancers most likely to respond to certain therapies remains a key goal. For example, microRNAs have been shown to differentiate effectively between micro-satellite instability positive and negative tumours using formalin-fixed, paraffin-embedded tissue of resection specimens [8]. Genetic aberrations have a significant impact on core tumour characteristics and clinical behaviour with better prognosis associated with micro-satellite instability-associated tumours.

Furthermore, microRNAs may play a role in helping to identify response to treatment. In one study, expression of high levels of miR-196a was associated with chemosensitivity towards platin derivatives [39].

Certain microRNAs have been shown to correlate with poorer prognosis [37,40]. Tumours expressing high levels of mir-21 and mir-200 have been shown to represent poorer prognosis and more aggressive disease. Similarly, mir-29a expression is associated with greater degrees of nodal positivity [33,40]. While further studies are necessary, the identification of markers of more aggressive disease would allow tailoring of therapy with these patients receiving more aggressive therapy. Not only does this hold the potential to more effectively treat patients with more aggressive disease,

it also provides a potential opportunity to spare patients with less aggressive disease from undergoing unnecessarily overzealous treatment. Therefore, elucidation of microRNA markers of disease severity or activity is crucial in the pursuit of improved oncologic outcome, optimum patient quality of life and increased cost-effectiveness.

7. Current practical challenges

Continued investigation into elucidation of microRNA expression in colorectal cancer is crucial in exploring the potential benefits of these promising biomarker candidates. In the laboratory setting, it is important to encourage international standardisation and optimisation of techniques. Only through stringent controls can we hope to arrive at reliable conclusions amenable to translation from bench to bedside. For example, the evaluation of optimum endogenous controls for colorectal cancer blood and tissue samples is crucial. To correct for systematic variables such as the quality of RNA in a given sample or the amount of template available, RQ-PCR data is commonly normalised to an endogenous control (EC) gene which should be expressed in a stable manner across a sample set [7]. A universal endogenous control is unlikely to exist, so, to avoid introducing further error in the quantification of expression data it is necessary that candidate ECs be evaluated and validated in colorectal cancer tissue, blood and cells [7].

Exosomes are small nano-vesicles released by many cells which are known to be present in plasma and other body fluids [9]. Exosomes are known to contain RNA [9]. Therefore, in extraction of RNA from cells, blood and tissue, many researchers now agree that ultracentrifugation steps be performed to avoid the presence of confounding exosomal RNA. In an extensive systematic review of microRNA biomarker candidates in colorectal cancer, Ma et al. reported on 6 microRNAs differentially expressed in colorectal cancer which are inconsistently reported to be over or under expressed in 3 or more studies [28]. Optimisation of laboratory techniques such as exosome isolation and use of appropriate endogenous controls may help to improve accuracy of identification of RNA expression.

8. Conclusion

Despite improvement in early diagnosis, surgical techniques, and general patient care, a large disparity in

5-year survival exists between stage one and stage four colorectal cancer. Patient prognosis is highly dependent on stage at diagnosis. This highlights a need for better understanding of tumour biology in order to identify novel biomarkers for early disease detection and individualisation of therapy. MicroRNAs hold enormous potential to revolutionize diagnostics and screening in colorectal cancer. Not only have they have been shown to be differentially expressed in colorectal cancer, microRNAs may also be capable of providing crucial information regarding response to therapy and core tumour characteristics. Furthermore, the detection of microRNAs in the circulation and faecal matter of patients with colorectal cancer may facilitate minimally invasive disease detection and characterisation.

References

- [1] Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. *Cancer Genomics Proteomics*. 2009 Sep-Oct; 6(5): 281-95.
- [2] Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. *BMC Cancer*. 2009; 9: 374.
- [3] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004 Jan 23; 116(2): 281-97.
- [4] Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene *p53* in *Drosophila*. *Cell*. 2003 Apr 4; 113(1): 25-36.
- [5] Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA*. 2002 Nov 26; 99(24): 15524-9.
- [6] Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, et al. The colorectal microRNAome. *Proc Natl Acad Sci USA*. 2006 Mar 7; 103(10): 3687-92.
- [7] Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. *BMC Mol Biol*. 2008; 9: 76.
- [8] Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. *J Mol Diagn*. 2010 Jul; 12(4): 433-40.
- [9] Eldh M, Lotvall J, Malmhall C, Ekstrom K. Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. *Mol Immunol*. 2012 Apr; 50(4): 278-86.
- [10] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. Dec 15; 127(12): 2893-917.
- [11] Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. *Lancet Oncol*. 2007 Mar; 8(3): 245-55.

- [12] Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.* 2006 Jan 1; 34(Database issue): D140-4.
- [13] Hannon GJ. RNA interference. *Nature.* 2002 Jul 11; 418 (6894): 244-51.
- [14] Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer.* 2002 Jan; 2(1): 38-47.
- [15] Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. *Ann Surg.* 2010 Mar; 251(3): 499-505.
- [16] Heusschen R, van Gink M, Griffioen AW, Thijssen VL. MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. *Biochim Biophys Acta.* 2010 Jan; 1805(1): 87-96.
- [17] Hogan NM, Dwyer RM, Joyce MR, Kerin MJ. Mesenchymal stem cells in the colorectal tumor microenvironment: recent progress and implications. *Int J Cancer.* 2012 Jul 1; 131(1): 1-7.
- [18] Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int J Cancer.* 2011 Jul 1; 127(1): 118-26.
- [19] Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, Roviello F, Sileri P, Cretella M, et al. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. *Br J Cancer.* 2011 May 24; 104(11): 1770-8.
- [20] Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. *Nat Rev Cancer.* 2002 Oct; 2(10): 727-39.
- [21] Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. *Cancer Res.* 2007 Jul 1; 67(13): 6304-13.
- [22] Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. A microRNA component of the hypoxic response. *Cell Death Differ.* 2008 Apr; 15(4): 667-71.
- [23] Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. *Mol Cell Biol.* 2007 Mar; 27(5): 1859-67.
- [24] Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. *Biomarkers.* 2006 Sep–Oct; 11(5): 385-405.
- [25] Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell.* 1993 Dec 3; 75(5): 843-54.
- [26] Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. *World J Surg.* 2009 Apr; 33(4): 667-84.
- [27] Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal microRNAs as novel biomarkers for colon cancer screening. *Cancer Epidemiol Biomarkers Prev.* 2010 Jul; 19(7): 1766-74.
- [28] Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. *Int J Cancer.* 2012 May 1; 130(9): 2077-87.
- [29] Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol Cancer Res.* 2003 Oct; 1(12): 882-91.
- [30] Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. *Eur J Surg Oncol.* 2009 Apr; 35(4): 339-47.
- [31] Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci USA.* 2008 Jul 29; 105(30): 10513-8.
- [32] Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. *Gut.* 2009 Oct; 58(10): 1375-81.
- [33] Nugent M, Miller N, Kerin MJ. MicroRNAs in colorectal cancer: function, dysregulation and potential as novel biomarkers. *Eur J Surg Oncol.* 2011 Aug; 37(8): 649-54.
- [34] O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst.* 2004 Oct 6; 96(19): 1420-5.
- [35] Pin AL, Houle F, Huot J. Recent advances in colorectal cancer research: the microenvironment impact. *Cancer Microenviron.* 2011 Aug; 4(2): 127-31.
- [36] Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. *Int J Biochem Cell Biol.* 2009 Aug; 42(8): 1291-7.
- [37] Sarver AL, French AJ, Borralho PM, Thayaniythy V, Oberg AL, Silverstein KA, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. *BMC Cancer.* 2009; 9: 401.
- [38] Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA.* 2008 Jan 30; 299(4): 425-36.
- [39] Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. *World J Gastroenterol.* 2009 May 7; 15(17): 2089-96.
- [40] Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. *Oncology.* 2007; 72(5–6): 397-402.
- [41] Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. *Mol Cancer.* 2009; 8: 102.
- [42] Tsang JC, Lo YM. Circulating nucleic acids in plasma/serum. *Pathology.* 2007 Apr; 39(2): 197-207.
- [43] Waldman SA, Terzic A. Translating MicroRNA discovery into clinical biomarkers in cancer. *JAMA.* 2007 May 2; 297(17): 1923-5.
- [44] Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer. *Br J Surg.* 2007 Jan; 94(1): 23-30.
- [45] Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. *RNA.* 2007 Oct; 13(10): 1668-74.
- [46] Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. *World J Surg.* 2009 Apr; 33(4): 638-46.
- [47] Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. *World J Gastroenterol.* 2007 May 28; 13(20): 2883-8.